This inventor holds 1 USPTO granted patent. Top assignee: Metagone Biotech Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: **Tai-Wei Ly: Innovator in Cancer Treatment**
Introduction
Tai-Wei Ly, an accomplished inventor based in Taipei, Taiwan, has made significant contributions to the fields of pharmaceutical science and oncology. He holds a patent for an innovative compound that is poised to advance cancer treatment methodologies. His work at Metagone Biotech Inc. reflects his commitment to developing effective therapeutic solutions.
Latest Patents
Tai-Wei Ly's patent is titled "Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof." This patent encompasses a novel compound, which is an ammonium salt of GW5074. The compound formula allows for various substitutions, providing flexibility in its applications. Notably, it includes a pharmaceutical kit designed for treating cancers. The kit comprises a c-Raf inhibitor and a second formulation containing the patented compound, demonstrating a dual approach to effectively target cancer cells.
Career Highlights
Tai-Wei Ly has established a notable career at Metagone Biotech Inc., where he has been involved in pioneering research that bridges the gap between drug development and clinical application. His innovative spirit is evident in his patent, which addresses a pressing need in cancer treatment options through a targeted therapeutic strategy.
Collaborations
Collaboration is key in the realm of innovation, and Tai-Wei Ly has worked alongside distinguished colleagues such as Tai-Lung Cha and Yi-Ta Tsai. These partnerships foster an environment where creative ideas can be translated into impactful inventions that advance healthcare.
Conclusion
Tai-Wei Ly is a prominent figure in the field of drug innovation, with a focus on oncology. His patent for ammonium salts marks a significant milestone in the fight against cancer, highlighting his dedication to improving patient outcomes through scientific advancement. As he continues his work at Metagone Biotech Inc., the future looks promising for further breakthroughs in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile